French pharma major Sanofi (Euronext: SAN) today posted first-quarter 2016 financials, with sales of 8.54 billion euros ($9.47 billion), almost flat (+0.7%) from last year or down 1.9% on a constant exchange rate basis. This was below analysts’ consensus forecast for 8.63 billion euros. The company’s shares were down 3.28% at 73.69 euros in late morning trading.
Earnings per share were up 1.5%, or 5.3% on a CER basis, at 1.34 euros, versus expectations for 1.29 euros. Net income for the quarter dipped 0.2% (+3.5% at constant exchange rates) at 1.72 billion euros.
Full-year 2016 guidance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze